keyword
MENU ▼
Read by QxMD icon Read
search

Budesonide

keyword
https://www.readbyqxmd.com/read/28427765/easl-clinical-practice-guidelines-the-diagnosis-and-management-of-patients-with-primary-biliary-cholangitis
#1
Gideon M Hirschfield, Ulrich Beuers, Christophe Corpechot, Pietro Invernizzi, David Jones, Marco Marzioni, Christoph Schramm
Primary biliary cholangitis (PBC) is a chronic inflammatory autoimmune cholestatic liver disease, which when untreated will culminate in end-stage biliary cirrhosis. Diagnosis is usually based on the presence of serum liver tests indicative of a cholestatic hepatitis in association with circulating antimitochondrial antibodies. Patient presentation and course can be diverse and risk stratification is important to ensure all patients receive a personalised approach to their care. The goals of treatment and management are the prevention of end-stage liver disease, and the amelioration of associated symptoms...
April 17, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28427362/efficacy-of-budesonide-formoterol-maintenance-and-reliever-therapy-compared-with-higher-dose-budesonide-as-step-up-from-low-dose-inhaled-corticosteroid-treatment
#2
Christine R Jenkins, Göran Eriksson, Eric D Bateman, Helen K Reddel, Malcolm R Sears, Magnus Lindberg, Paul M O'Byrne
BACKGROUND: Asthma management may involve a step up in treatment when symptoms are not well controlled. We examined whether budesonide/formoterol maintenance and reliever therapy (MRT) is as effective as higher, fixed-dose budesonide plus as-needed terbutaline in patients requiring step-up from Step 2 treatment (low-dose inhaled corticosteroids), stratified by baseline reliever use. METHODS: A post-hoc analysis utilized data from three clinical trials of 6-12 months' duration...
April 20, 2017: BMC Pulmonary Medicine
https://www.readbyqxmd.com/read/28425305/development-of-a-soluplus%C3%A2-budesonide-freeze-dried-powder-for-nasal-drug-delivery
#3
Michele Pozzoli, Daniela Traini, Paul M Young, Maria B Sukkar, Fabio Sonvico
OBJECTIVE: The aim of this work was to develop an amorphous solid dispersions/solutions (ASD) of a poorly soluble drug, Budesonide (BUD) with a novel polymer Soluplus(®) (BASF, Germany) using a freeze-drying technique, in order to improve dissolution and absorption through the nasal route. SIGNIFICANCE: The small volume of fluid present in the nasal cavity limits the absorption of a poorly soluble drug. Budesonide is a corticosteroid, practically insoluble, and normally administered as a suspension-based nasal spray...
April 20, 2017: Drug Development and Industrial Pharmacy
https://www.readbyqxmd.com/read/28425216/pneumonia-risk-in-asthma-patients-using-inhaled-corticosteroids-a-quasi-cohort-study
#4
Christina J Qian, Janie Coulombe, Samy Suissa, Pierre Ernst
AIM: Studies have linked the use of inhaled corticosteroids (ICS) to excess pneumonia risk in COPD patients. The risk in asthma patients remains unclear. The objective was to examine the risk of pneumonia with ICS in patients 12 to 35 years old with asthma. METHODS: We formed a cohort of asthma patients treated from 1990-2007 using Quebec health insurance databases. Subjects were considered currently exposed if they had an ICS dispensed within the 60 days prior to their pneumonia index event or matched person-moment...
March 28, 2017: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28420280/enteric-coated-budesonide-for-the-induction-and-maintenance-of-remission-of-crohn-s-disease-in-children
#5
Stanley A Cohen, Marina Aloi, Ramalingam Arumugam, Robert Baker, Kevin Bax, Jaroslaw Kierkuś, Sibylle Koletzko, Paolo Lionetti, Tore Persson, Stefan Eklund
OBJECTIVE: These studies evaluated the safety and efficacy of enteric-coated budesonide for the induction and maintenance of remission of mild-to-moderate Crohn's disease (CD) in children. METHODS: The consecutive, multicenter, open-label, non-comparative studies enrolled patients aged 6-17 years. In the induction study, patients with active CD of the ileum and/or ascending colon received budesonide 9 mg or 6 mg once daily for 8 weeks; in the maintenance study, patients in remission received budesonide 6 mg once daily for 12 weeks...
April 19, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28412691/clinical-effect-of-treatment-on-elderly-chronic-obstructive-pulmonary-disease-combined-with-pulmonary-tuberculosis
#6
Xiuwu Liu, Chenling Tang, Huimin Xu
OBJECTIVE: To explore and analyze the clinical therapeutic schedule of elderly chronic obstructive pulmonary disease combined with pulmonary tuberculosis. METHOD: This clinical research analysis chooses the 2000 patients suffered elderly chronic obstructive pulmonary disease combined with pulmonary tuberculosis treated in the hospital during June of 2014 and June of 2015 as the object of observation. These 2000 cases are randomly divided into experimental group and control group...
November 2016: Pakistan Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28399021/an-update-on-the-treatment-of-iga-nephropathy
#7
Sean Barbour, John Feehally
PURPOSE OF REVIEW: The treatment of IgA nephropathy (IgAN) has been limited by several controversies in the literature, including the benefits of corticosteroids in addition to optimized renin-angiotensin system blockers (RASBs), in those with lower estimated glomerular filtration rate (eGFR), or in different ethnic groups. Recent studies have attempted to address these issues. RECENT FINDINGS: Two observational studies suggest the efficacy of corticosteroids in those with lower eGFR, but with a higher risk of adverse events...
April 8, 2017: Current Opinion in Nephrology and Hypertension
https://www.readbyqxmd.com/read/28389744/the-gut-kidney-axis-in-iga-nephropathy-role-of-microbiota-and-diet-on-genetic-predisposition
#8
Rosanna Coppo
Recent data suggest that gut-associated lymphoid tissue (GALT) plays a major role in the development of immunoglobulin A (IgA) nephropathy (IgAN). A genome-wide association study showed that most loci associated with the risk of IgAN are also associated with immune-mediated inflammatory bowel diseases, maintenance of the intestinal barrier and regulation of response to gut pathogens. Studies involving experimental models have demonstrated a pivotal role of intestinal microbiota in the development of IgAN in mice producing high levels of IgA and in transgenic mice overexpressing BAFF, a B-cell factor crucial for IgA synthesis, indicating the role of genetic background, B-cell activity, GALT intestinal immunity and diet...
April 7, 2017: Pediatric Nephrology: Journal of the International Pediatric Nephrology Association
https://www.readbyqxmd.com/read/28387094/-formoterol-budesonide-combination-for-maintenance-and-relief-in-children-and-adolescents-with-asthma
#9
REVIEW
G de Bilderling, D Smal, E Bradatan
International guidelines have been edited to standardize asthma management. These guidelines are often difficult to translate to clinical practice because of gaps in the knowledge of clinical practitioners but also because of compliance issues, particularly in children and adolescents. A new approach named SIT (for Single Inhaler Therapy) or SMART (for Symbicort Maintenance and Reliever Therapy) has demonstrated its safety and efficacy in numerous studies of adults with asthma summarized in two Cochrane reviews...
December 2016: Revue Médicale de Liège
https://www.readbyqxmd.com/read/28383629/ip-10-in-occupational-asthma-review-of-the-literature-and-case-control-study
#10
F Ragusa, P Fallahi
OBJECTIVES: T-helper (Th)2 cytokines are thought to mediate most of the allergic inflammatory responses associated with atopic asthma. But the Th1-related chemokine, interferon (IFN)-γ-induced protein 10 (IP-10)/chemokine (C-X-C motif) ligand (CXCL)10, was the predominant chemokine measured during human allergic pulmonary late-phase reaction. Viral infection and allergens can exacerbate asthma by inducing the accumulation of these chemokines and inflammatory cells in the airway. Short-acting β2-adrenoreceptor agonists, budesonide and formoterol (all important relievers in asthma exacerbation), such as vitamin D3, vitamin C, have been shown to inhibit airway cells inflammatory responses by modulating these chemokines...
March 2017: La Clinica Terapeutica
https://www.readbyqxmd.com/read/28375647/fulfil-trial-once-daily-triple-therapy-in-patients-with-chronic-obstructive-pulmonary-disease
#11
David A Lipson, Helen Barnacle, Ruby Birk, Noushin Brealey, Nicholas Locantore, David A Lomas, Andrea Ludwig-Sengpiel, Rajat Mohindra, Maggie Tabberer, Chang-Qing Zhu, Steven J Pascoe
RATIONALE: Randomized data comparing triple therapy with dual inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) therapy in patients with chronic obstructive pulmonary disease (COPD) are limited. OBJECTIVES: We compared the effects of once-daily triple therapy on lung function and health-related quality of life with twice-daily ICS/LABA therapy. METHODS: FULFIL was a randomized, double-blind, double-dummy study comparing 24 weeks of once-daily triple therapy (fluticasone furoate/umeclidinium/vilanterol 100 μg/62...
April 4, 2017: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/28371296/population-exposure-to-phthalate-containing-drugs
#12
Anne Broe, Zandra Nymand Ennis, Anton Pottegård, Jesper Hallas, Thomas Ahern, Per Damkier
Phthalates are known endocrine disruptors. Not commonly recognised, phthalates are used as excipients in a number of drug formulations. We aimed to describe the sale of phthalate-containing drugs in Denmark from 2004 to 2015. National data on annual sale of medications (tablets only) were accessed from medstat.dk. Data from the Danish Medicines Agency on phthalate content per tablet were merged with data on total sale for each active substance and drug formulation. We used the 'defined daily dose' (DDD) as the unit of sale and calculated the total amount of phthalate (mg) dispensed per 1,000 inhabitants...
March 29, 2017: Basic & Clinical Pharmacology & Toxicology
https://www.readbyqxmd.com/read/28367177/bronchoscopy-for-foreign-body-aspiration-and-effects-of-nebulized-albuterol-and-budesonide-combination
#13
Bulent Akcora, Mehmet Emin Celikkaya, Cahit Ozer
OBJECTIVE: A foreign body aspiration in the tracheobronchial tree is a dangerous medical condition in the childhood period. Although rigid bronchoscopy is a safe procedure, it may cause complications. The aim of this study was to present our bronchoscopy experience and to evaluate the efficacy of pre-operative administration of nebulized albuterol and budesonide combination for reducing intra-operative complications in foreign body aspirated cases. METHODS: In this retrospective study our pediatric cases in which a foreign body was removed from tracheobronchial tree in last 8 years were analyzed...
January 2017: Pakistan Journal of Medical Sciences Quarterly
https://www.readbyqxmd.com/read/28363480/targeted-release-budesonide-versus-placebo-in-patients-with-iga-nephropathy-nefigan-a-double-blind-randomised-placebo-controlled-phase-2b-trial
#14
Bengt C Fellström, Jonathan Barratt, Heather Cook, Rosanna Coppo, John Feehally, Johan W de Fijter, Jürgen Floege, Gerd Hetzel, Alan G Jardine, Francesco Locatelli, Bart D Maes, Alex Mercer, Fernanda Ortiz, Manuel Praga, Søren S Sørensen, Vladimir Tesar, Lucia Del Vecchio
BACKGROUND: IgA nephropathy is thought to be associated with mucosal immune system dysfunction, which manifests as renal IgA deposition that leads to impairment and end-stage renal disease in 20-40% of patients within 10-20 years. In this trial (NEFIGAN) we aimed to assess safety and efficacy of a novel targeted-release formulation of budesonide (TRF-budesonide), designed to deliver the drug to the distal ileum in patients with IgA nephropathy. METHODS: We did a randomised, double-blind, placebo-controlled phase 2b trial, comprised of 6-month run-in, 9-month treatment, and 3-month follow-up phases at 62 nephrology clinics across ten European countries...
March 28, 2017: Lancet
https://www.readbyqxmd.com/read/28358425/ormdl3-is-associated-with-airway-remodeling-in-asthma-via-the-erk-mmp-9-pathway
#15
Fei Yu, Yan Sun, Jiachen Yu, Zhen Ding, Jinrong Wang, Lanyun Zhang, Tiejing Zhang, Yun Bai, Yulin Wang
ORMDL sphingolipid biosynthesis regulator 3 (ORMDL3) has been previously implicated in asthma pathogenesis, its effect on airway remodeling remains to be elucidated. The present study examined the expression levels of ORMDL3 in a mouse model of asthma. Mice were divided into three groups: Asthmatic model (n=10), budesonide‑treated (n=10) and a control group (n=8). Asthma was induced by sensitization with ovalbumin (OVA) and aluminum hydroxide on day 1, 7 and 14. Subsequently mice were exposed to OVA three times per week from day 28...
March 30, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/28352347/one-mechanism-of-glucocorticoid-action-in-asthma-may-involve-the-inhibition-of-il-25-expression
#16
Wei Lu, Chao Lu, Chengming Zhang, Chenghao Zhang
While the mechanism of action of classic cytokines in asthma has received increased attention from researchers, certain non-classical cytokines, such as IL-25, also participate in this mechanism. The present study was performed to investigate the changes in IL-25 (IL-17E) mRNA and protein in bronchial asthma and to further characterize the mechanism underlying the action of glucocorticoids in asthma. A total of 96 specific pathogen-free BALB/c male mice were randomly divided into three normal groups (after the first allergization, after the second allergization and after excitation), three asthma groups (with the same three subgroups), a dexamethasone group and a budesonide group (n=12/group)...
February 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28333362/budesonide-multi-matrix-is-efficacious-for-mesalamine-refractory-mild-to-moderate-ulcerative-colitis-a-randomized-placebo-controlled-trial
#17
David T Rubin, Russell D Cohen, William J Sandborn, Gary R Lichtenstein, Jeffrey Axler, Robert H Riddell, Cindy Zhu, Andrew C Barrett, Enoch Bortey, William P Forbes
Background and Aims.: Safety and efficacy of budesonide multimatrix, an oral extended-release second-generation corticosteroid designed for targeted delivery throughout the colon, was examined for induction of remission in patients with mild to moderate ulcerative colitis refractory to baseline mesalamine therapy. Methods.: A randomized, double-blind, placebo-controlled, multicenter trial evaluated efficacy and safety of budesonide multimatrix for induction of remission [ulcerative colitis disease activity index score ≥ 4 and ≤ 10] in 510 adults randomized to once-daily oral budesonide multimatrix 9 mg or placebo for 8 weeks...
March 4, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28333203/budesonide-mmx-add-on-to-5-aminosalicylic-acid-therapy-in-mild-to-moderate-ulcerative-colitis-a-favourable-risk-benefit-profile
#18
Silvio Danese, Stefanos Bonovas, Laurent Peyrin-Biroulet
No abstract text is available yet for this article.
February 21, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28332899/in-vitro-tests-for-aerosol-deposition-v-using-realistic-testing-to-estimate-variations-in-aerosol-properties-at-the-trachea
#19
Xiangyin Wei, Michael Hindle, Renishkumar R Delvadia, Peter R Byron
BACKGROUND: The dose and aerodynamic particle size distribution (APSD) of drug aerosols' exiting models of the mouth and throat (MT) during a realistic inhalation profile (IP) may be estimated in vitro and designated Total Lung Dose, TLDin vitro, and APSDTLDin vitro, respectively. These aerosol characteristics likely define the drug's regional distribution in the lung. METHODS: A general method was evaluated to enable the simultaneous determination of TLDin vitro and APSDTLDin vitro for budesonide aerosols' exiting small, medium and large VCU-MT models...
March 23, 2017: Journal of Aerosol Medicine and Pulmonary Drug Delivery
https://www.readbyqxmd.com/read/28330503/caffeine-modulates-glucocorticoid-induced-expression-of-ctgf-in-lung-epithelial-cells-and-fibroblasts
#20
Markus Fehrholz, Kirsten Glaser, Christian P Speer, Silvia Seidenspinner, Barbara Ottensmeier, Steffen Kunzmann
BACKGROUND: Although caffeine and glucocorticoids are frequently used to treat chronic lung disease in preterm neonates, potential interactions are largely unknown. While anti-inflammatory effects of glucocorticoids are well defined, their impact on airway remodeling is less characterized. Caffeine has been ascribed to positive effects on airway inflammation as well as remodeling. Connective tissue growth factor (CTGF, CCN2) plays a key role in airway remodeling and has been implicated in the pathogenesis of chronic lung diseases such as bronchopulmonary dysplasia (BPD) in preterm infants...
March 23, 2017: Respiratory Research
keyword
keyword
15056
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"